AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Neratinib'
:
Adaptive Randomization of Neratinib in Early Breast Cancer
Publication Year: 2016
DOI: https://doi.org/10.1056/nejmoa1513750
Abstract:
Add to Library
Authors:
John W. Park
Minetta C. Liu
Douglas Yee
Christina Yau
Laura van ‘t Veer
W. Fraser Symmans
Melissa Paoloni
Jane Perlmutter
Nola M. Hylton
Michael Hogarth
Angela DeMichele
Meredith Buxton
A. Jo Chien
Anne M. Wallace
Judy C. Boughey
Tufia C. Haddad
Jane Yuet Ching Hui
Kathleen Kemmer
Henry G. Kaplan
Claudine Isaacs
Rita Nanda
Debasish Tripathy
Kathy S. Albain
Kirsten K. Edmiston
Anthony Elias
Donald W. Northfelt
Lajos Pusztai
Stacy L. Moulder
Julie E. Lang
Rebecca K. Viscusi
David Euhus
Barbara Haley
Qamar J. Khan
William C. Wood
Michelle Melisko
Richard B. Schwab
Teresa Helsten
Julia Lyandres
Sarah Davis
Gillian L. Hirst
Ashish Sanil
Laura J. Esserman
Donald A. Berry
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
Publication Year: 2010
DOI: https://doi.org/10.1200/jco.2009.25.8707
Abstract:
Add to Library
Authors:
Harold J. Burstein
Yan Sun
Luc Dirix
Zefei Jiang
Robert Paridaens
Antoinette R. Tan
Ahmad Awada
Anantbhushan Ranade
Shunchang Jiao
Gary K. Schwartz
Richat Abbas
Christine Powell
Kathleen Turnbull
Jennifer Vermette
Charles Zacharchuk
Rajendra Badwe
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
Publication Year: 2010
DOI: https://doi.org/10.1200/jco.2009.27.9414
Abstract:
Add to Library
Authors:
Lecia V. Sequist
Benjamin Besse
Thomas J. Lynch
Vincent A. Miller
Kwok‐Kin Wong
Barbara J. Gitlitz
Keith D. Eaton
Charles Zacharchuk
Amy Freyman
Christine Powell
Revathi Ananthakrishnan
Susan Quinn
Jean‐Charles Soria
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
Publication Year: 2009
DOI: https://doi.org/10.1158/1078-0432.ccr-08-1978
Abstract:
Add to Library
Authors:
Kwok-K. Wong
Paula M. Fracasso
Ronald M. Bukowski
Thomas J. Lynch
Pamela N. Münster
Geoffrey I. Shapiro
Pasi A. Jänne
Joseph P. Eder
Michael Naughton
Matthew J. Ellis
Suzanne F. Jones
Tarek Mekhail
Charles Zacharchuk
Jennifer Vermette
Richat Abbas
Susan Quinn
Christine Powell
Howard A. Burris
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer
Publication Year: 2016
DOI: https://doi.org/10.1001/jamaoncol.2016.0237
Abstract:
Add to Library
Authors:
Ahmad Awada
Rámón Colomer
Kenichi Inoue
Igor Bondarenko
Rajendra Badwe
Georgia Demetriou
Soo Chin Lee
Ajay Mehta
Sung‐Bae Kim
Thomas Bachelot
Chanchal Goswami
Suryanarayan V.S. Deo
Ron Bose
Alvin Wong
Feng Xu
Bin Yao
Richard Bryce
Lisa A. Carey
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Publication Year: 2013
DOI: https://doi.org/10.18632/oncotarget.1148
Abstract:
Add to Library
Authors:
Alexandra Canonici
Merel Gijsen
Maeve Mullooly
Ruth Bennett
Noujoude Bouguern
Kasper Pedersen
Neil A. O’Brien
Ioannis Roxanis
Jiliang Li
Esther Bridge
Richard S. Finn
Dennis J. Slamon
Patricia M. McGowan
Michael J. Duffy
Norma O’Donovan
John Crown
Anthony Kong
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Publication Year: 2020
DOI: https://doi.org/10.1200/jco.20.00147
Abstract:
Add to Library
Authors:
Cristina Saura
Mafalda Oliveira
Yin‐Hsun Feng
Ming‐Shen Dai
Shang-Wen Chen
Sara A. Hurvitz
Sung‐Bae Kim
Beverly Moy
Suzette Delaloge
William J. Gradishar
Norikazu Masuda
Markéta Palácová
Maureen Trudeau
Johanna Mattson
Yoon Sim Yap
Ming‐Feng Hou
Michelino De Laurentiis
Yu‐Min Yeh
Hong‐Tai Chang
Thomas Yau
Hans Wildiers
Barbara Haley
Daniele Fagnani
Yen‐Shen Lu
John Crown
Johnson Lin
Masato Takahashi
Toshimi Takano
Miki Yamaguchi
Takaaki Fujii
Bin Yao
Judith D. Bebchuk
Kiana Keyvanjah
Richard Bryce
Adam Brufsky
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Publication Year: 2016
DOI: https://doi.org/10.1016/s1470-2045(15)00551-3
Abstract:
Add to Library
Authors:
Arlene Chan
Suzette Delaloge
Frankie A. Holmes
Beverly Moy
Hiroji Iwata
Vernon Harvey
Nicholas J. Robert
Tajana Silovski
Erhan Gökmen
Gϋnter von Minckwitz
Bent Ejlertsen
Stephen Chia
Janine Mansi
Carlos H. Barrios
Michael Gnant
Marc Buyse
Ira Gore
John W. Smith
Graydon Harker
Norikazu Masuda
Katarína Petráková
Ángel Guerrero Zotano
Nicholas Iannotti
Gladys Rodriguez
Pierfrancesco Tassone
Alvin Wong
Richard Bryce
Yining Ye
Bin Yao
Miguel Martín
Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors
Publication Year: 2013
DOI: https://doi.org/10.1200/jco.2012.47.2787
Abstract:
Add to Library
Authors:
Leena Gandhi
Rastislav Bahleda
Sara M. Tolaney
Eunice L. Kwak
James M. Cleary
Shuchi S. Pandya
Antoine Hollebecque
Richat Abbas
Revathi Ananthakrishnan
Anna Berkenblit
Mizue Krygowski
Yali Liang
Kathleen Turnbull
Geoffrey I. Shapiro
Jean‐Charles Soria
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Publication Year: 2017
DOI: https://doi.org/10.1016/s1470-2045(17)30717-9
Abstract:
Add to Library
Authors:
Miguel Martín
Frankie A. Holmes
Bent Ejlertsen
Suzette Delaloge
Beverly Moy
Hiroji Iwata
Gϋnter von Minckwitz
Stephen Chia
Janine Mansi
Carlos H. Barrios
Michael Gnant
Z. Tomasevic
Neelima Denduluri
Robert Šeparović
Erhan Gökmen
Anna Bashford
Manuel Ruíz Borrego
Sung‐Bae Kim
Erik Jakobsen
A. Ciceniene
Kenichi Inoue
Friedrich Overkamp
Joan B. Heijns
Anne Armstrong
John S. Link
Anil A. Joy
Richard Bryce
Alvin Wong
Susan Moran
Bin Yao
Feng Xu
Alan Auerbach
Marc Buyse
Arlene Chan
Vernon Harvey
Rudolf Tomek
Nicholas J. Robert
Ira Gore
John W. Smith
Norikazu Masuda
S. Di Sean Kendall
William Graydon Harker
Katarína Petráková
Ángel Guerrero-Zotano
Amparo Ruiz Simón
Zora Neskovic Konstantinovic
Nicholas Iannotti
Pierfrancesco Tassone
Gladys Rodriguez
Noelia Jáñez Martínez
Carmen Crespo Massieu
Snezana Smickoska
Işıl Somali
Uğur Yılmaz
Mirta Garcia Alonso
Adolfo Rosales
Soeren Cold
Ann Knoop
Debra A. Patt
Beth A. Hellerstedt
Serafín Morales
Ingrid A. Mayer
Julie A. Means‐Powell
Rina Hui
Francis M. Senecal
Richard Hendry De Boer
Zhenzhou Shen
Adam Andrzej Luczak
Joanna W.Y. Chui
Janice Tsang
István Láng
Yoshiaki Rai
Yasuo Hozumi
Albert J. ten Tije
Manish Bhandari
Cynthia R. Osborne
Shoichiro Ohtani
Kenji Higaki
Kenichi Watanabe
Kazunori TAGUCHI
Masato Takahashi
Sladjana Filipovic
Vincent Hansen
Vijayarama Phooshkooru Rao
Manish Gupta
Petar Petrov
Bruno Coudert
Željko Vojnović
Zsofia Polya
Toshiko Miyaki
Naohito Yamamoto
Stephen Brincat
Krzysztof Leśniewski-Kmak
Ewa Chmielowska
Ruemu Birhiray
Marc L. Citron
Steven W. Papish
William L. Berry
Sven Tyge Langkjer
José Á. García-Sáenz
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
Publication Year: 2019
DOI: https://doi.org/10.1200/jco.18.01511
Abstract:
Add to Library
Authors:
Rachel A. Freedman
Rebecca Gelman
Carey K. Anders
Michelle Melisko
Heather A. Parsons
Anne M. Cropp
Kelly M. Silvestri
Christine M. Cotter
Kathryn P. Componeschi
Juan M. Marte
Roisín M. Connolly
Beverly Moy
Catherine Van Poznak
Kimberly Blackwell
Shannon L. Puhalla
Rachel C. Jankowitz
Karen L. Smith
Nuhad K. Ibrahim
Timothy J. Moynihan
Ciara C. O’Sullivan
Julie R. Nangia
Polly Niravath
Nadine Tung
Paula R. Pohlmann
Robyn Burns
Mothaffar F. Rimawi
Ian E. Krop
Antonio C. Wolff
Eric P. Winer
Nancy U. Lin
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial
Publication Year: 2016
DOI: https://doi.org/10.17615/tfn3-9835
Abstract:
Add to Library
Authors:
Ahmad Awada
Rámón Colomer
Kenichi Inoue
Igor Bondarenko
Rajendra Badwe
Georgia Demetriou
Soo Chin Lee
Ajay Mehta
Sung‐Bae Kim
Thomas Bachelot
Chanchal Goswami
Suryanarayan V.S. Deo
Ron Bose
Alvin Wong
Feng Xu
Bin Yao
Richard Bryce
Lisa A. Carey
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Publication Year: 2020
DOI: https://doi.org/10.1016/j.clbc.2020.09.014
Abstract:
Add to Library
Authors:
Arlene Chan
Beverly Moy
Janine Mansi
Bent Ejlertsen
Frankie A. Holmes
Stephen Chia
Hiroji Iwata
Michael Gnant
Sibylle Loibl
Carlos H. Barrios
Işıl Somali
Snezhana Smichkoska
Noelia Martínez-Jáñez
Mirta Garcia Alonso
John S. Link
Ingrid A. Mayer
Søren Cold
Serafín Morales
Francis M. Senecal
Kenichi Inoue
Manuel Ruíz‐Borrego
Rina Hui
Neelima Denduluri
Debra A. Patt
Hope S. Rugo
Stephen Johnston
Richard Bryce
Bo Zhang
Feng Xu
Alvin Wong
Miguel Martín
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
Publication Year: 2016
DOI: https://doi.org/10.1200/jco.2015.63.0343
Abstract:
Add to Library
Authors:
Rachel A. Freedman
Rebecca Gelman
Jeffrey S. Wefel
Michelle Melisko
Kenneth R. Hess
Roisín M. Connolly
Catherine Van Poznak
Polly Niravath
Shannon L. Puhalla
Nuhad K. Ibrahim
Kimberly Blackwell
Beverly Moy
Christina I. Herold
Minetta C. Liu
Alarice Lowe
Nathalie Y.R. Agar
Nicole Ryabin
Sarah Farooq
Elizabeth Lawler
Mothaffar F. Rimawi
Ian E. Krop
Antonio C. Wolff
Eric P. Winer
Nancy U. Lin
Neratinib: First Global Approval
Publication Year: 2017
DOI: https://doi.org/10.1007/s40265-017-0811-4
Abstract:
Add to Library
Authors:
Found 6101 results in 0.041 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"